Hirmand Mohammad 4

4 · Turning Point Therapeutics, Inc. · Filed Jan 5, 2021

Form 4

Period: 2021-01-04

EVP and Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option (right to buy)
2021-01-05−1,253→ 169,192 total
Exercise: $54.73Exp: 2029-12-01→ Common Stock (1,253 underlying)
Exercise/Conversion
Common Stock
2021-01-05$54.73/sh+1,253$68,577→ 1,537 total
Exercise/Conversion
Stock Option (right to buy)
2021-01-04−8,747→ 170,445 total
Exercise: $54.73Exp: 2029-12-01→ Common Stock (8,747 underlying)
Sale
Common Stock
2021-01-04$122.44/sh−300$36,732→ 9,031 total
Sale
Common Stock
2021-01-04$120.42/sh−8,747$1,053,314→ 284 total
Exercise/Conversion
Common Stock
2021-01-04$54.73/sh+8,747$478,723→ 9,331 total
Sale
Common Stock
2021-01-05$120.00/sh−1,253$150,360→ 284 total

Footnotes (4)

[F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
[F2]The Reporting Person acquired 300 shares on June 12, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 284 shares on December 10, 2020 pursuant the ESPP.
[F3]The weighted average sale price for the transaction reported was $120.42, and the range of prices were between $120.00 and $121.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F4]25% of the shares vest on December 2, 2020 and 1/48th of the shares vest monthly thereafter over the next three years.

Documents

1 file